Stryker stock gains 1.77 percent as quarterly growth holds
📈 Stryker reported adjusted quarterly EPS of $3.69, beating the consensus estimate of $3.49.
💰 Revenue reached $6.59 billion, representing a 9.40% increase from the comparable quarter.
🎯 The company issued full-year 2026 adjusted EPS guidance between $14.95 and $15.10.
💵 Stryker declared a quarterly dividend of $0.88 per share with an ex-dividend date of September 30, 2026.
📉 Analyst Canaccord Genuity reduced its price target from $400.00 to $385.00 while maintaining a Buy rating.
📊 The stock gained 1.77% to trade at EUR 246.65, though it remains below its 52-week high of $392.55.
🗓️ Investors await the next quarterly report on October 29, 2026, to validate the full-year outlook.
Bullish Signals
- Stryker delivered adjusted EPS of $3.69, exceeding analyst expectations of $3.49.
- Revenue grew 9.40% year-over-year to reach $6.59 billion, surpassing the $6.58 billion consensus.
- The company provided full-year 2026 EPS guidance of $14.95-$15.10, indicating sustained growth expectations.
- Stryker declared a quarterly dividend of $0.88 per share, returning capital to shareholders.
Risk Factors
- Analyst Canaccord Genuity reduced its price target from $400.00 to $385.00, reflecting some caution despite the Buy rating.
- The stock trades below its 52-week high of $392.55, suggesting potential room for upside or lingering valuation concerns.
Full Analysis
Stryker Corporation reported strong quarterly financial results, with adjusted earnings per share reaching $3.69, surpassing the consensus estimate of $3.49. Revenue for the quarter totaled $6.59 billion, slightly exceeding expectations and marking a 9.40% increase year-over-year. These figures indicate that the medical device maker is maintaining its growth trajectory despite broader market scrutiny.
The company provided full-year 2026 adjusted EPS guidance ranging between $14.95 and $15.10, signaling confidence in its operational performance for the remainder of the fiscal year. Additionally, Stryker declared a quarterly dividend of $0.88 per share, with an ex-dividend date set for September 30, 2026, offering immediate value to shareholders while reinforcing its commitment to returning capital.
Despite the positive operating data, analyst sentiment remains mixed due to recent target price reductions. Canaccord Genuity lowered its price target from $400.00 to $385.00 while retaining a Buy rating, contributing to a moderate buy consensus with an average target of $374.42. The stock traded up 1.77% on the day, though it remains below its 52-week high.
Market participants are closely watching the upcoming quarterly report scheduled for October 29, 2026, to determine if the company can sustain its current run rate against the full-year guidance. With a market capitalization of approximately $106.8 billion, Stryker continues to be a significant player in the healthcare and medical devices sector.
